Hypoprothrombinemia During Cefmetazole Treatment: A Case Report.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
27 07 2022
27 07 2022
Historique:
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
BACKGROUND Cefmetazole (CMZ), containing an N-methyl-tetrazole-thiol (NMTT) side chain, is a therapeutic option for diverticulitis in Japan. Cephems containing an NMTT, a methyl-thiadiazol, and a thiadiazolethiol side chain are known to induce coagulation disorders. CASE REPORT A 76-year-old woman developed hypoprothrombinemia after receiving oral levofloxacin (LVFX) 250 mg q24h for 2 days followed by intravenous CMZ 2 g q8h for sigmoid diverticulitis. On day 5 of CMZ administration (after 12 doses in total), black stool was observed. On the following day (after 14 doses), prothrombin time (PT) prolongation was noted; PT and international normalized ratio (INR) were 37.1 s and 2.47, respectively. We diagnosed the patient with hypoprothrombinemia because of vitamin K deficiency caused by markedly elevated protein levels induced by vitamin K absence or antagonist-II on day 6 of CMZ administration. Intravenous vitamin K administration and CMZ cessation rapidly restored PT and led to the disappearance of black stool. CONCLUSIONS The causes of vitamin K deficiency were considered to be an impaired vitamin K cycle due to CMZ and decreased vitamin K intake because of malnutrition. These findings are consistent with CMZ's reported adverse effects. Decreased vitamin K production due to alterations in the gut bacterial flora by LVFX and CMZ was also postulated as a cause. If a bleeding tendency is noted during diverticulitis treatment with NMTT-containing cephems, switching to intravenous quinolones or carbapenems is recommended. It remains unclear how this reaction can be avoided; however, prudent monitoring of bleeding signs and PT-INR is recommended.
Identifiants
pubmed: 35891595
pii: 936712
doi: 10.12659/AJCR.936712
pmc: PMC9340825
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vitamin K
12001-79-5
Cefmetazole
3J962UJT8H
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e936712Commentaires et corrections
Type : ErratumIn
Références
J Nutr Sci Vitaminol (Tokyo). 1992;Spec No:421-4
pubmed: 1297780
Am Fam Physician. 2013 May 1;87(9):612-20
pubmed: 23668524
J Thromb Thrombolysis. 2011 May;31(4):419-23
pubmed: 21181236
J Chemother. 2020 May;32(3):118-123
pubmed: 32096456
Am J Nephrol. 2017;45(1):1-3
pubmed: 27842304
Surg Infect (Larchmt). 2002 Fall;3(3):161-73
pubmed: 12542922
J Antimicrob Chemother. 1989 Apr;23 Suppl D:47-54
pubmed: 2722723
J Antimicrob Chemother. 1984 Sep;14 Suppl B:325-30
pubmed: 6389475
Anaesth Crit Care Pain Med. 2018 Apr;37(2):167-170
pubmed: 28870850
J Pharm Pract. 2020 Jun;33(3):378-381
pubmed: 30189787
AMA Arch Intern Med. 1957 Dec;100(6):986-8
pubmed: 13478207
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Nihon Naika Gakkai Zasshi. 1984 Jul;73(7):986-94
pubmed: 6491464
Case Rep Med. 2019 Jan 21;2019:3574064
pubmed: 30805005
Ann Pharmacother. 1997 Feb;31(2):180-4
pubmed: 9034420
Thromb Res. 1986 Oct 15;44(2):147-53
pubmed: 3787564
PLoS One. 2016 Jul 27;11(7):e0158407
pubmed: 27463687
Gan To Kagaku Ryoho. 2020 Feb;47(2):352-354
pubmed: 32381986
Am Surg. 2010 Feb;76(2):168-71
pubmed: 20336894
Lancet. 1980 Jan 5;1(8158):39-40
pubmed: 6101371
J Gen Fam Med. 2017 Jun 21;18(5):258-260
pubmed: 29264036